Trial Profile
Phase 2 Study of Cytarabine in Association With Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Cytarabine (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms CyBeR-Lymph
- 21 Apr 2021 Status changed from not yet recruiting to discontinued.
- 05 May 2016 New trial record